Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

AstraZeneca Submits First Atypical Antipsychotic For Anxiety Indication

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Supplemental NDA package for Seroquel XR includes data from four clinical studies, all of which met their primary endpoints.

You may also be interested in...



AstraZeneca’s Seroquel Cleared For Longer Use In Bipolars

FDA says yes to adjunct maintenance with lithium or divalproex.

AstraZeneca’s Seroquel Cleared For Longer Use In Bipolars

FDA says yes to adjunct maintenance with lithium or divalproex.

AstraZeneca Submits Seroquel XR In Two Additional Indications

Company is seeking approval of separate sNDAs for treatment of bipolar mania and bipolar depression.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

US WorldMeds’ Eflornithine Gets US FDA Panel Nod For Pediatric Neuroblastoma

US FDA Versus Its Own Precedents

US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons

New ePortal To Simplify Processing & Tracking Of WHO Prequalification Applications

See All
UsernamePublicRestriction

Register

PS067869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By